A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer.

Published in: Journal of gynecologic oncology (2024)

This study could not demonstrate that adding Bev to ddTC improves prognosis. Further studies with more cases are warranted.

Keyphrases